LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)

Espinar, J; Torri, Valter; Whisenant, Jennifer G.; Hirsch, F. R.; Rogado, Jacobo; Carpeño, Javier de Castro; Halmos, Balázs; Ceresoli, Giovanni Luca; Rueda, A. Gómez; Tiseo, Marcello; Felip, Enriqueta; Tarruella, M. Majem; Monnet, I.; Tapan, Umit; Wakelee, Heather A.; Huang, Li; Garassino, Marina Chiara; Peters, Solange; Horn, Leora; Hellmann, Matthew D.

doi:10.1016/j.annonc.2020.08.2316

Cited by 15 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 28 In an updated analysis of 1012 patients presented at ESMO, patients receiving chemotherapy alone or not receiving treatment had worse outcomes compared with patients receiving immunotherapy, chemoimmunotherapy, or targeted therapy (HR 1.4, 95% CI 1.02 to 2.0, p=0.03). 29 In a single center analysis of 102 patients with lung cancer treated at Memorial Sloan Kettering, no effect of recent systemic therapy was seen on COVID-19 outcomes, including chemotherapy or chemoimmunotherapy. 27 In the CCC-19 registry, which includes patients of multiple tumor types, the highest 30-day mortality by treatment type was chemoimmunotherapy at 30% 30-day mortality.…”

Section: Lung Cancer Treatment and Covid-19mentioning

confidence: 99%

“…The updated results based on 1012 patients showed higher mortality (32%) and hospitalization rate (72%), compared with a dramatic low ICU admission (12%) and mechanical ventilation rate (7%). 29 …”

Section: Mortality Rate Across Main Registries and Seriesmentioning

confidence: 99%

“…The average delay of oncologic treatment for patients in the TERAVOLT registry was 21 days. 29 The Centers for Disease Control and Prevention (CDC) recommends immunocompetent individuals with COVID-19 quarantine for 10 days, while those considered immunocompromised quarantine for 20 days. 46 It remains to be seen how treatment delays will affect patient’s cancer outcomes.…”

Section: Lung Cancer Treatment and Covid-19mentioning

confidence: 99%

“… 28 In expanded analysis presented at both ASCO and ESMO, patients receiving targeted therapies do not have increased risk of death in multivariate analysis. 29 30 The degree to which this relatively favorable outcome is related to the mechanisms of these therapies as opposed to the different demographics of the patients who use them (younger, non-smokers) is not fully understood.…”

Section: Lung Cancer Treatment and Covid-19mentioning

confidence: 99%

See 3 more Smart Citations

Severity of COVID-19 in patients with lung cancer: evidence and challenges

Passaro

Bestvina

Velez

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

Cancer patients are highly vulnerable to SARS-CoV-2 infections due to frequent contacts with the healthcare system, immunocompromised state from cancer or its therapies, supportive medications such as steroids and most importantly their advanced age and comorbidities. Patients with lung cancer have consistently been reported to suffer from an increased risk of death compared with other cancers. This is possibly due to the combination of specific pathophysiological aspects, including underlying pulmonary compromise due to smoking history and the increased specific pressures on respiratory healthcare services caused by the related pandemic. Rationally and safely treating patients with lung cancer during the pandemic has become a continuous challenge over the last year. Deciding whether to offer, modify, postpone or even cancel treatments for this particular patient’s population has become the crucial recurrent dilemma for lung cancer professionals. Chemotherapy, immunotherapy and targeted agents represent distinct risks factors in the context of COVID-19 that should be balanced with the short-term and long-term consequences of delaying cancer care. Despite the rapid and persistent trend of the pandemic, declared by WHO on March 11, 2020, and still ongoing at the time of writing (January 2021), various efforts were made by oncologists worldwide to understand the impact of COVID-19 on patients with cancer. Adapted recommendations of our evidence-based practice guidelines have been developed for all stakeholders. Different small and large-scale registries, such as the COVID-19 and Cancer Consortium (CCC19) and Thoracic Cancers International COVID-19 Collaboration quickly collected data, supporting cancer care decisions under the challenging circumstance created by the COVID-19 pandemic. Several recommendations were developed as guidance for prioritizing the various aspects of lung cancer care in order to mitigate the adverse effects of the COVID-19 healthcare crisis, potentially reducing the morbidity and mortality of our patients from COVID-19 and from cancer. These recommendations helped inform decisions about treatment of established disease, continuation of clinical research and lung cancer screening. In this review, we summarize available evidence regarding the direct and indirect impact of the COVID-19 pandemic on lung cancer care and patients.

show abstract

Section: Lung Cancer Treatment and Covid-19mentioning

confidence: 99%

Section: Mortality Rate Across Main Registries and Seriesmentioning

confidence: 99%

Section: Lung Cancer Treatment and Covid-19mentioning

confidence: 99%

Section: Lung Cancer Treatment and Covid-19mentioning

confidence: 99%

See 2 more Smart Citations

Severity of COVID-19 in patients with lung cancer: evidence and challenges

Passaro

Bestvina

Velez

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…Les résultats actualisés au 15 juillet 2020 ont été présentés au meeting virtuel de l’ESMO en septembre 2020 [ 9 ]. L’analyse sur 1012 patients pris en charge, dans 20 pays, montre un âge médian de 68 ans, 58 % d’hommes, 80 % de fumeurs actifs ou ex fumeurs.…”

Section: éPidémiologieunclassified

Cancer du poumon à l’ère du COVID-19

Chouaïd

2020

Revue des Maladies Respiratoires Actualités

View full text Add to dashboard Cite

L’épidémie à Covid-19 a considérablement mis sous tension les systèmes de soins de l’ensemble des pays. Les impacts sont multiples en particulier pour les patients pris en charge pour un cancer. L’objectif de ce travail est de résumer les données épidémiologiques disponibles sur les patients avec cancer du poumon développant une infection Covid, en particulier les facteurs de risque d’aggravation et de mortalité, de décrire les différentes stratégies pour améliorer la prise en charge de ces patients et de résumer les recommandations existantes dans ce domaine. Sur le plan épidémiologique, la plus large cohorte sur ce sujet, Teravolt, qui a inclus 1012 patients, retrouve un taux d’hospitalisation de 72 %, un taux d’aggravation de 56 % et une mortalité de 32 %. En analyse multivariée, l’âge ≥ 65 ans (OR 1,53 CI 1,11-2,1), un tabagisme actif (OR 2 CI 1,3-3), le statut métastatique (OR 1,9 CI 1,3-2,7), un ECOG PS ≥ 2 (OR 3,7 CI 2,7-5), la prise de corticostéroïdes avant l’infection COVID (OR 1,8 CI 1,2-2,7) sont associés à un risqué plus élevé de mortalité, mais pas un traitement par chimiothérapie ou par thérapie ciblée. De manière intéressante, le traitement par immunothérapie semble diminuer le risque de mortalité (OR 0,6 CI 0,97) Plusieurs stratégies de dépistage des formes asymptomatiques sont rapportées dans la littérature et semblent utiles pour diagnostiquer des formes asymptomatiques chez des patients en cours de traitement systémiques ou de radiothérapie. Enfin les recommandations nationales et internationales convergent sur de nombreux points en particulier la nécessité de protéger du Covid le patient et sa famille en évaluant au cas par cas le bénéfice/risque des prises en charge. © 2020 SPLF. Publié par Elsevier Masson SAS. Tous droits réservés.

show abstract

Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19

et al. 2022

View full text Add to dashboard Cite

IMPORTANCELarge cohorts of patients with active cancers and COVID-19 infection are needed to provide evidence of the association of recent cancer treatment and cancer type with COVID-19 mortality. OBJECTIVE To evaluate whether systemic anticancer treatments (SACTs), tumor subtypes, patient demographic characteristics (age and sex), and comorbidities are associated with COVID-19 mortality. DESIGN, SETTING, AND PARTICIPANTS The UK Coronavirus Cancer Monitoring Project (UKCCMP) is a prospective cohort study conducted at 69 UK cancer hospitals among adult patients (Ն18 years) with an active cancer and a clinical diagnosis of COVID-19. Patients registered from March 18 to August 1, 2020, were included in this analysis.EXPOSURES SACT, tumor subtype, patient demographic characteristics (eg, age, sex, body mass index, race and ethnicity, smoking history), and comorbidities were investigated. MAIN OUTCOMES AND MEASURESThe primary end point was all-cause mortality within the primary hospitalization. RESULTSOverall, 2515 of 2786 patients registered during the study period were included; 1464 (58%) were men; and the median (IQR) age was 72 (62-80) years. The mortality rate was 38% (966 patients). The data suggest an association between higher mortality in patients with hematological malignant neoplasms irrespective of recent SACT, particularly in those with acute leukemias or myelodysplastic syndrome (OR, 2.16; 95% CI, 1.30-3.60) and myeloma or plasmacytoma (OR, 1.53; 95% CI, 1.04-2.26). Lung cancer was also significantly associated with higher COVID-19-related mortality (OR, 1.58; 95% CI,. No association between higher mortality and receiving chemotherapy in the 4 weeks before COVID-19 diagnosis was observed after correcting for the crucial confounders of age, sex, and comorbidities. An association between lower mortality and receiving immunotherapy in the 4 weeks before COVID-19 diagnosis was observed (immunotherapy vs no cancer therapy: OR, 0.52; 95% CI, 0.31-0.86). CONCLUSIONS AND RELEVANCEThe findings of this study of patients with active cancer suggest that recent SACT is not associated with inferior outcomes from COVID-19 infection. This has relevance for the care of patients with cancer requiring treatment, particularly in countries experiencing an increase in COVID-19 case numbers. Important differences in outcomes among patients with hematological and lung cancers were observed.

show abstract

LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)

Cited by 15 publications

References 0 publications

Severity of COVID-19 in patients with lung cancer: evidence and challenges

Severity of COVID-19 in patients with lung cancer: evidence and challenges

Cancer du poumon à l’ère du COVID-19

Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19

Contact Info

Product

Resources

About